Ann: Appendix 4C - quarterly, page-29

Thanks glutenfree, I like your charts. I have also come up with some similar results but I have also included other income (R and D tax benefit) which has the effect of reducing the operating expenses by around $0.5m pa. On that basis annual operating expenses reduce from roughly $2.9m to $2.4m which is around where the ACV ($2.41m) currently sits. Operating cash flow is lagging the ACV by some 3-6 months so we may expect, all going well, cash flow breakeven to occur in the near future and the cash flow shortfall to be reducing significantly. Only my thoughts and many things can happen to impact the above. One of which is the additional new products currently under development by 3DP. DYOR